System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Caroline Gaudy-Marqueste is an expert in Dermatology at Hôpitaux universitaires de Marseille (France). As of October 2026, ScienceLeadR ranks Caroline Gaudy-Marqueste in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Caroline Gaudy-Marqueste has authored 356 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 3 of them ongoing. SLR score: 1,008 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Caroline Gaudy-Marqueste Hôpitaux universitaires de Marseille France
1 008 ScienceLeadR Reputation 1008

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Hôpitaux universitaires de Marseille

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 356

Citations

Citations: 6 071 1st author: 43 Last author: 18 Unique author: 3

Main journals

Ann Dermatol Venereol 114
J Clin Oncol 20
Eur J Cancer 16
Annales de dermatologie et de vénéréologie, FMC 14
J Eur Acad Dermatol Venereol 10

Best Journals

J Clin Oncol 13
Ann Oncol 6
Nat Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.
PMID 42926136 — confidence intervals, safety, molecular biology, melanoma, biomarkers, nivolumab		Nat Med Top journal20260
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
PMID 42826365 — safety, melanoma, neoplasms, precision medicine, therapeutics		JCO Precis Oncol20260
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.
PMID 42601381 — cells, catenins, cell differentiation, melanoma, neoplasm metastasis, carcinogenesis, therapeutics, cell death		Cell Death Differ20260
Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).
PMID 42582160 — injections, herpes simplex, blood, neoplasms, simplexvirus, viruses, therapeutics, infections		Front Oncol20261

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 9
Phase 3 5
N/A 4
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 9
Active not recruiting 4
Recruiting 4
Terminated 3

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 2
multicentricup10 15

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
NEOREM NEO 1 NEOREM Neo adjuvant Immunotherapy Master Trial for Localized Cancers NEO 1 Neo adjuvant immunotherapy in patients with localized melanoma
2025-522127-95-00 — quality of life, disease-free survival, melanoma, neoplasms, immunotherapy, therapeutics		Phase 2Recruiting2026
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Neo adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613 — injections, melanoma, neoplasms, solutions, immunotherapy, neoadjuvant therapy, nivolumab, therapeutics, ipilimumab		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS